PF-05212377
- Generic Name
- PF-05212377
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H20N4O2S
- CAS Number
- 1226793-34-5
- Unique Ingredient Identifier
- 4JEH3BL51N
- Background
PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms on Donepezil).
- Associated Conditions
- -
- Associated Therapies
- -
A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT02005991
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2011-07-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01258751
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Scopolamine Challenge Study
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT01213355
- Locations
- 🇫🇷
Pfizer Investigational Site, Rennes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath